Valuation dashboard for Kodiak Sciences Inc. (KOD) with P/E N/A, P/B 101.37, EV/EBITDA -29.0 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At $98.89 (closing price, November 3, 2026), KOD has negative trailing earnings (P/E not meaningful) and an ROE of -273.23%. Market capitalisation stands at $6.2B.
Balance sheet quality for KOD: debt-to-equity ratio of 1.57, current ratio of 2.49 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 101.37 |
| EV / EBITDA | -29.0 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| KOD | Kodiak Sciences Inc. | $6.2B | 101.37 | -273.2% | |
| REGN | Regeneron Pharmaceuticals, Inc. | $100.2B | 21.51 | 2.96 | 15.1% |
| BLTE | Belite Bio, Inc | $6.1B | 7.93 | -15.6% | |
| BLCO | Bausch + Lomb Corporation | $7.2B | 1.11 | -1.7% | |
| VRTX | Vertex Pharmaceuticals Incorporated | $134.5B | 34.15 | 6.44 | 20.1% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $134.0B | 30.25 | 6.57 | 23.3% |
| MRNA | Moderna, Inc. | $91.2B | 13.38 | -39.2% | |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $86.5B | 19.22 | 2.62 | 13.8% |
Price
| Price | $98.89 (closing price, November 3, 2026) |
| Market Cap | $6.2B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -273.23% |
| Return on Invested Capital | -115.23% |
| Return on Assets | -94.23% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: REGN · BLTE · BLCO · VRTX · 0QZU.L · MRNA · 0R2M.L · ARGX
Explore sector: Healthcare · Biotechnology
More sections of KOD: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks